426 related articles for article (PubMed ID: 23177488)
21. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
22. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
23. Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review.
Svoboda M; Poprach A; Dobes S; Kiss I; Vyzula R
Cardiovasc Toxicol; 2012 Sep; 12(3):191-207. PubMed ID: 22528816
[TBL] [Abstract][Full Text] [Related]
24. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
Ky B; Carver JR
Heart Fail Clin; 2011 Jul; 7(3):323-31. PubMed ID: 21749884
[TBL] [Abstract][Full Text] [Related]
25. [Cardiotoxicity of cancer therapy].
Marek J; Linhart A; Rucklová Z; Haber J; Korínek J
Vnitr Lek; 2011 May; 57(5):472-84. PubMed ID: 21695928
[TBL] [Abstract][Full Text] [Related]
26. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
27. [Cardiac prevention: the oncologic point of view].
Gligorov J; Debourdeau P; Arsovski O; Lotz JP
Bull Cancer; 2004 Nov; 91 Suppl 3():192-200. PubMed ID: 15899627
[TBL] [Abstract][Full Text] [Related]
28. Cardiotoxicity.
Brana I; Tabernero J
Ann Oncol; 2010 Oct; 21 Suppl 7():vii173-9. PubMed ID: 20943611
[TBL] [Abstract][Full Text] [Related]
29. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
[TBL] [Abstract][Full Text] [Related]
30. Use of non-anthracycline regimens in early stage breast cancer in Australia.
de Boer RH; Chan A; Tran B; Wilcken N
Asia Pac J Clin Oncol; 2011 Mar; 7(1):4-10. PubMed ID: 21332644
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy-related cardiotoxicity: new diagnostic and preventive strategies.
Benvenuto GM; Ometto R; Fontanelli A; Fortunato A; Ruffini PA; Fosser V; Morandi P
Ital Heart J; 2003 Oct; 4(10):655-67. PubMed ID: 14664278
[TBL] [Abstract][Full Text] [Related]
32. Cardiac toxicity from systemic cancer therapy: a comprehensive review.
Curigliano G; Mayer EL; Burstein HJ; Winer EP; Goldhirsch A
Prog Cardiovasc Dis; 2010; 53(2):94-104. PubMed ID: 20728696
[TBL] [Abstract][Full Text] [Related]
33. Cardiotoxicity of systemic agents used in breast cancer.
Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
[TBL] [Abstract][Full Text] [Related]
34. [The diagnosis of anthracycline-induced cardiac damage and heart failure].
Dudka J; Burdan F; Korga A; Dyndor K; Syroka I; Zieba J; Lewkowicz D; Korobowicz-Markiewicz A
Postepy Hig Med Dosw (Online); 2009 May; 63():225-33. PubMed ID: 19502683
[TBL] [Abstract][Full Text] [Related]
35. Natriuretic peptides: biochemical markers of anthracycline cardiac toxicity?
Urbanova D; Urban L; Danova K; Simkova I
Oncol Res; 2008; 17(2):51-8. PubMed ID: 18543606
[TBL] [Abstract][Full Text] [Related]
36. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography.
Pichon MF; Cvitkovic F; Hacene K; Delaunay J; Lokiec F; Collignon MA; Pecking AP
In Vivo; 2005; 19(3):567-76. PubMed ID: 15875778
[TBL] [Abstract][Full Text] [Related]
37. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer.
Youssef G; Links M
Am J Cardiovasc Drugs; 2005; 5(4):233-43. PubMed ID: 15984906
[TBL] [Abstract][Full Text] [Related]
38. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
Simůnek T; Klimtová I; Kaplanová J; Mazurová Y; Adamcová M; Sterba M; Hrdina R; Gersl V
Eur J Heart Fail; 2004 Jun; 6(4):377-87. PubMed ID: 15182761
[TBL] [Abstract][Full Text] [Related]
39. [Chemotherapeutics-induced heart failure].
Paulides M; Wojnowski L
Med Klin (Munich); 2007 Jul; 102(7):574-8. PubMed ID: 17634876
[TBL] [Abstract][Full Text] [Related]
40. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.
Armenian SH; Gelehrter SK; Vase T; Venkatramani R; Landier W; Wilson KD; Herrera C; Reichman L; Menteer JD; Mascarenhas L; Freyer DR; Venkataraman K; Bhatia S
Clin Cancer Res; 2014 Dec; 20(24):6314-23. PubMed ID: 24947931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
